Skip to main content

Table 4 Pan-cancer Therapy Efficacy model performance assessed using overall survival

From: The impact of pharmacokinetic gene profiles across human cancers

  Univariate Multivariate
Rulea Genomics features Low-risk (N) High-risk (N) High-risk (%) HR [95% CI] p-value HR [95% CI] p-value
Export 1 2749 109 3.8 1.49 [1.09, 2.05] 1.2 × 10−2 1.49 [1.13, 1.96] 4.7 × 10− 3
Import 1 2777 81 2.8 0.90 [0.61, 1.33] 6.0 × 10−1 1.00 [0.76, 1.32] 1.0 × 100
Metabolism 1 2642 216 7.6 1.26 [0.94, 1.69] 1.3 × 10−1 1.12 [0.85, 1.48] 4.2 × 10− 1
Metabolismb 1 2809 49 1.7 1.74 [1.09, 2.77] 2.1 × 10− 2 1.73 [1.31, 2.28] 9.3 × 10− 5
Target 1 2780 78 2.7 1.12 [0.76, 1.66] 5.6 × 10− 1 1.07 [0.81, 1.41] 6.3 × 10− 1
Any-Hit 3 2530 328 11.5 1.21 [0.94, 1.55] 1.4 × 10− 1 1.17 [0.88, 1.53] 2.8 × 10− 1
Any-PK-Hit 2 2660 198 6.9 1.26 [0.97, 1.64] 7.8 × 10−2 1.27 [0.96, 1.67] 9.4 × 10− 2
Efficacy Model 2 2715 143 5.0 1.41 [1.06, 1.88] 1.9 × 10−2 1.47 [1.11, 1.93] 6.3 × 10− 3
  1. aRules based on tumor-genomic features; see Methods for definitions
  2. bRequiring at least two metabolism genes affected; see Additional file 1: Figure S1 for additional comparisons